about
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and UveitisClinical efficacy of Shodhana Karma and Shamana Karma in Mandala Kushtha (Psoriasis)Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisSubclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic studyObjective assessment of psoriasis erythema for PASI scoring.Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabFirst-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasisCalcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightEstimating transformations for repeated measures modeling of continuous bounded outcome data.Value of entheseal ultrasonography and serum cartilage oligomeric matrix protein in the preclinical diagnosis of psoriatic arthritis.The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritisIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perioXP-828l in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study.The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians.Psoriatic arthritis assessment tools in clinical trials.Patient-centered online management of psoriasis: a randomized controlled equivalency trialThe Assessment of Selected Bone and Cartilage Biomarkers in Psoriatic Patients from Poland.TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus.Topical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation.US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Portable handheld diffuse reflectance spectroscopy system for clinical evaluation of skin: a pilot study in psoriasis patientsImmunobiologics in the treatment of psoriasis.IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities.Development of outcome measures for autoimmune dermatoses.Treatment of severe psoriasis with infliximab.Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.The effect of weight loss in obese patients with chronic stable plaque-type psoriasis.Novel immunobiologics for psoriasis.Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting.Briakinumab for the treatment of plaque psoriasis.Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses.Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.New topical treatments for psoriasis.Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis.Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
P2860
Q22299388-212EB54A-C591-415E-8691-F506D0D99AEBQ24598003-0D913E05-9EB6-4515-80FA-280B62C66199Q28744054-464AA41A-A70F-46AD-9E61-9A19B030D055Q30361133-BDBC0FF2-5E12-499A-909F-9571C42CAA21Q33488248-AA1A44B0-BAF0-4F0A-98FA-4C32AD6B5BCBQ33573621-D3951FFA-4671-4F54-8272-4F0361CFBE46Q33593625-C84AD36D-1CF8-4C02-B2E8-31AA94AF78C8Q33650112-FFB8BE8B-BE0F-4BA8-A394-8C7DA0C8C058Q33729774-D8AAECAF-8827-4114-82CD-1B5322971F8AQ33864905-03A7D671-1C8D-4609-8B21-3A586B3E0260Q34340028-668DE848-25C1-4A65-AECA-923DB7B03919Q34393068-DFAC7DE5-D8AE-4772-93D1-F4865010DFCDQ34485175-FF420ECA-0065-48C5-A04D-20CF37574DEAQ34538249-0D6D3F33-CD26-4945-B8CC-7626FE53FAB4Q34603524-49614992-6489-4FA1-A5D9-56C2039454E9Q34730794-8CE66A6B-C6F1-4CC1-AA19-863705A92A76Q35175365-B60E9251-7ADA-4CC7-9ADB-7EA609D056B7Q35579462-82252FFC-16D7-4BE3-BBC8-A2A6F27F0786Q35600818-390FF115-1843-47AC-BF6E-A3B0ABCDFD82Q35753415-10E70CA6-EA66-4412-A6A2-90FAFEBAC522Q35858608-806286E9-61C0-4F5D-83DD-49E408BB82EFQ35897906-ABD981EB-8203-4C2C-9F06-2F610BE3DAB2Q36521222-54E4FAE6-E8F2-49B7-9434-398789465C43Q36631743-034C5E5C-F80E-413A-B1B5-31D810CA5B23Q36743142-2FA19E8C-96A7-420B-B086-FE008E793874Q36807407-8CE68041-4E04-4962-9E56-292C8A1608FAQ36994240-608FA23B-31D7-40D9-9B42-04A09D6EB6A0Q37098135-8ED74E4E-2799-43D4-A215-B9D3DA5F3574Q37118011-EC56D93A-53B5-477A-906B-BE0372B8D650Q37212524-77FC183B-28D9-425C-929F-1478D85393E1Q37664478-7BA98D1D-3258-4D64-B1E0-E9FD2C9C2672Q37862369-C1EA4F2A-AF0F-47E6-8AC5-7DDCDF4CFB16Q37955218-CECD520E-AC44-4E06-9B5A-B90185CE22D8Q38064467-239A34DA-8521-4F6E-B91A-C3A5F7C34281Q38075774-5321E265-34C9-4F55-A6FA-12BB68B13335Q38176057-8B4C9864-1ED7-465D-AECD-798491CEF83BQ38211315-77E76EE9-3536-4C82-8826-9A01CDF37432Q38379906-0D750CC7-BBAD-4755-8FC4-DF045C1400ACQ38388241-69AAE05C-A462-4244-8B81-8EBA13147C7BQ38545195-2B9B1842-7FBE-4D41-ACA5-49A6F9C10F58
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Psoriasis assessment tools in clinical trials.
@ast
Psoriasis assessment tools in clinical trials.
@en
type
label
Psoriasis assessment tools in clinical trials.
@ast
Psoriasis assessment tools in clinical trials.
@en
prefLabel
Psoriasis assessment tools in clinical trials.
@ast
Psoriasis assessment tools in clinical trials.
@en
P2860
P356
P1476
Psoriasis assessment tools in clinical trials.
@en
P2093
Feldman SR
Krueger GG
P2860
P304
ii65-8; discussion ii69-73
P356
10.1136/ARD.2004.031237
P407
P478
64 Suppl 2
P577
2005-03-01T00:00:00Z